Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline in HFpEF Patients With Anxiety-Depressive Symptoms
2024-515061-33-00Phase 3Completed
- Sponsor
- Medical University of Gdańsk
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), major depressive disorder (MDD) and anxiety disorder comparing Asentra (sertraline) with Placebo or standard care control (2 arms). Primary endpoint: Time to hospitalization for cardiovascular reasons or death from any cause. Started Dec 2024; status: completed.
02
Drugs
sertraline
03
Conditions
heart failure with preserved ejection fraction (HFpEF)major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on 2024-515061-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515061-33-00.